GM 1485
Alternative Names: GM-1485; GPI-1485; NIL-ALatest Information Update: 28 May 2024
At a glance
- Originator MGI GP
- Developer GliaMed
- Class Lactones; Macrolides; Neuroprotectants; Small molecules
- Mechanism of Action Immunophilin modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bone disorders; Cartilage disorders; Myocardial infarction; Wounds
- Discontinued Dementia; Erectile dysfunction; HIV-associated nephropathy; Parkinson's disease
Most Recent Events
- 28 May 2024 No recent reports of development identified for preclinical development in Myocardial-infarction in USA
- 28 May 2024 No recent reports of development identified for research development in Bone-disorders in USA
- 28 May 2024 No recent reports of development identified for research development in Cartilage-disorders in USA